Transposable elements are mobile genetic elements of which two classes are distinguished based on their respective transposition mechanisms. The mobility of class I elements or retrotransposons is achieved through an RNA intermediate of a 'copy-and-paste' mechanism, whereas class II or DNA transposons use a DNA-mediated, 'cut-and-paste' mode of transposition (Fig. 1a) . The most abundant transposons in mammals are non-long terminal repeat retrotransposons represented by the long interspersed nuclear elements and the short interspersed nuclear elements. The major long interspersed nuclear elements in humans and rodents (LINE-1 or L1) contain two open reading frames (Fig. 1b) . These encode a nucleic acid binding protein and an enzyme with endonuclease and reverse transcriptase activity, respectively 1,2 . Endonuclease generates a single-stranded nick in the target DNA, and reverse transcriptase uses the nicked DNA to prime reverse transcription from the 3′ end of the L1 RNA 3,4 .
Transposable elements are DNA segments with the unique ability to move about in the genome. This inherent feature can be exploited to harness these elements as gene vectors for genome manipulation. Transposon-based genetic strategies have been established in vertebrate species over the last decade, and current progress in this field suggests that transposable elements will serve as indispensable tools. In particular, transposons can be applied as vectors for somatic and germline transgenesis, and as insertional mutagens in both loss-of-function and gain-offunction forward mutagenesis screens. In addition, transposons will gain importance in future cell-based clinical applications, including nonviral gene transfer into stem cells and the rapidly developing field of induced pluripotent stem cells. Here we provide an overview of transposon-based methods used in vertebrate model organisms with an emphasis on the mouse system and highlight the most important considerations concerning genetic applications of the transposon systems.
safety considerations. On the contrary, mutagenesis screens can capitalize on elements that tend to land in genes. The insertion pattern of most transposons is nonrandom, with many 'hotspots' and 'cold regions' on a genome-wide scale. Common hotspots represent the main limitation to full genome coverage with individual transposable element-based vectors. The preferences of particular elements to integrate into expressed genes versus noncoding DNA, and preferences for integration sites within genes are expected to be substantially different. Thus, in this respect, the utility of transposons for mutagenesis is greatly enhanced by the availability of multiple, alternative vector systems with distinct preferences for insertion ( Table 1) .
Transposons as vecTors for TransgenesIs stable gene transfer into stem cells and generation of ipscs
Transposon-based technologies can be used for gene transfer in cultured cells. For example, to integrate plasmid-based short hairpin RNA expression cassettes into chromosomes to obtain stable knockdown cell lines by RNA interference 15 . Furthermore, transposons are promising vectors for therapeutic gene delivery to facilitate clinical implementation of gene-and cell-based therapies 16 . A genetic screen in mammalian cells yielded a hyperactive SB transposase (SB100X) with ~100-fold enhancement in efficiency when compared to the first-generation transposase. SB100X supported 35-50% stable gene transfer in human CD34 + hematopoietic stem or progenitor cells that were proficient in multilineage hematopoietic reconstitution after transplantation into immunodeficient mice 17 . Thus, the efficiency of stable gene transfer by this hyperactive SB system approaches that of viral methods and therefore may be developed into an efficient, simple and cheap method for genetic manipulation of stem cells and other primary cell types.
The recent discovery of induced pluripotent stem cells (iPSCs) holds enormous promise for future regenerative medicine. By Drosophila 6 for transgenesis and insertional mutagenesis, but until the reactivation of the Sleeping Beauty (SB) transposon system in 1997 (ref. 7) , there was no indication of DNA-based transposons in vertebrates sufficiently active for these purposes. Later on, other elements have been shown to catalyze efficient transposition in vertebrate model organisms; their characteristics are summarized in Table 1 . The basic criteria for the applicability of a class II transposable element in any given model organism are (i) sufficient transpositional activity in the given species and (ii) a lack of endogenous copies in the targeted genome or other strategies that avoid mobilization of resident copies. Other practical considerations for the design of a particular gene transfer experiment include cargo capacity of the transposable element and integration site preference 8 .
capacity for cargo
Tolerance for cargo size varies greatly between transposable elements ( Table 1) . Members of the Tc1/mariner family, including SB, are inhibited by large size 9 . A particular modification of the SB transposon in this respect was the generation of a 'sandwich' transposon vector that has two complete SB elements flanking a transgene to be mobilized 10 . The sandwich SB vector enhanced transposition of large (>10 kb) transgene constructs and therefore probably is the method of choice for transgene constructs that would otherwise transpose poorly owing to their large size. The piggyBac 11 , Tol1 (ref. 12) and Tol2 (refs. 13,14) transposons appear to be more tolerant to larger cargo, allowing complex transgene designs to be incorporated within the transposon without sacrificing transposition efficiency. 20, 21 . One caveat that still remains is the possibility of the transposon to jump into a new location during the factor removal process. A way to solve this problem would be to develop a transposase that allows cutting but is deficient in pasting. Nevertheless, the transposon system-assisted reprogramming is looking forward to a bright future in regenerative medicine.
Integration site preference

Transgenesis in oocytes and embryos
Classical methods to stably express foreign genes in vertebrates rely on microinjection of gene constructs into oocytes or fertilized eggs. Three main drawbacks of this method are the low rate of genomic integration (<10%), the integration of injected DNA as a concatemer that is prone to silencing 22 , and that founders are predominantly mosaic for the transgene because integration generally occurs relatively late during embryonic development. All of these expressing only four genes (encoding transcription factors Oct4, Sox2, Klf4 and c-Myc), somatic cells can be transformed to a pluripotent state with a developmental capacity similar to that of embryonic stem cells 18 . Initially, this could only be achieved by retro-or lentiviral transduction. However, owing to safety issues, permanent viral insertions limit the value of the resulting iPSCs for clinical applications. Two special features of the transposon systems make them a promising alternative. First, the efficiency of transgene insertion by the piggyBac transposon 19 and by the recently developed hyperactive variant of SB 17 is comparable to that of viral transduction. Second, because transposon excision is not always followed by pasting into a new genomic location, the 'cut' component of the transposition offers removal of the transgenes after completion of reprogramming. Transpositionmediated generation of mouse and human iPSCs and traceless removal of the reprogramming factors from the pluripotent cells 0% of insertions in genes 60 Mouse and human cells 60 naTure meThods | VOL.6 NO.6 | JUNE 2009 | 417 revIew and whole-animal levels. However, this gene-by-gene approach does not facilitate gene discoveries related to a particular pathway of interest on a genome-wide scale. Genome-wide, forward insertional mutagenesis provides a powerful and high-throughput means to ascribe functions to genes associated with particular biological pathways. Insertional mutagenesis using engineered transposable elements can be one of the most productive and versatile approaches to disrupt and manipulate genes on a genome-wide scale. However, even if a transposable element inserts into a gene, it may not have a mutagenic effect. For example, intronic insertions are likely spliced out without having an effect on gene expression (Fig.  2a) . Thus, various technologies have been established to enhance the mutagenicity as well as reporting capabilities of insertional vectors by 'trapping' transcription units ( Fig. 2b-e) .
recessive genetic screens in embryonic stem cells
In cell culture systems, transposon delivery can be achieved by transfection of plasmid DNA containing the transposons or by mobilizing a chromosomally located transposon that has been placed in the genome by gene targeting or a prior transposition event. Transfection-based, 'plasmid-to-genome' delivery ( Fig. 3a) yields relatively unbiased genome-wide integrations; however, careful titration of the amount of the donor and transposase plasmid is required to provide the appropriate copy number per cell of the transposon. Intragenomic, 'genome-to-genome' mobilization ( Fig. 3b) can be selected based on excision and reintegration 35 , allowing efficient genome-wide mutagenesis and tight control over the copy number. Pluripotent mouse embryonic stem cells are attractive models for in vitro mutagenesis because they can differentiate into many cell types including the germline and because they are amenable to sophisticated genetic manipulation.
However, insertional mutagenesis in somatic cells is challenged by the diploid genome. Inactivation of both copies of a gene is nearly always required to evoke a phenotypic change, but the probability of generating bi-allelic mutations of a single locus by two independent 'hits' is extremely low. However, a system has been developed in embryonic stem cells that combines insertional mutagenesis with a Blm-deficient genetic background. Blm-deficient embryonic stem cells have a high rate of homologous recombination between homologous chromosomes, thereby promoting the conversion of single-allele mutations to bi-allelic mutations by loss of heterozygosity 36, 37 (Supplementary Fig. 1 online) . A typical recessive genetic screen using Blm-deficient embryonic stem cells (Supplementary Fig. 1 ) includes: (i) genome-wide mutagenesis drawbacks can be circumvented by using transposition-mediated gene delivery as it increases the efficiency of chromosomal integration and facilitates single-copy insertion events. The injection of in vitro-synthesized mRNA as a transposase source can further enhance the efficiency of this technique because of the more rapid availability of the transposase, resulting in reduced transgene mosaicism in the embryo and therefore elevated germline transmission rates. This method has been used for germline transgenesis in Ciona intestinalis with Minos 23 11 . The recently developed hyperactive SB100X transposase yields average transgenic frequencies of 45% in mouse embryos 17 , indicating that this hyperactive transposon system can be developed into a simple and efficient tool for transgenesis in vertebrates.
Transposon-medIaTed forward geneTIc approaches
Gene targeting has been very successful in generating altered alleles of specific genes, particularly in embryonic stem cells, allowing individual gene function to be dissected at the cellular 42, 44, 47, 48 . However, recombination between newly transposed transposon copies and the donor concatemer could lead to unwanted genomic rearrangements 50 . The SB100X hyperactive transposase is ~120-fold more active in mobilizing single-copy, chromosomally resident transposons than the wildtype transposase 17 and may thus potentially eliminate the need for concatemeric donor sites in genetic screens.
The Minos transposon has also been shown to mobilize in mice by transposase expression in oocytes using Zp3 (ref. 52 ) and in lymphocytes using Cd2 promoters 53 . PiggyBac has been used in mice 11, 54 , and the activity of the Tol2 element has already been demonstrated in mouse embryonic stem cells 55 and in vivo in the mouse liver 13 . In zebrafish, SB and Tol2 have been shown to be useful for insertional mutagenesis in coinjection experiments 27,56-59 . As discussed above, the availability of a battery of vector systems based on diverse transposable elements will undoubtedly increase genome coverage in mutagenesis screens.
Screens using the L1 retrotransposon. Mutagenesis screens using the L1 retrotransposon in mice are similar to the scheme shown in Figure 4 , except that only a single transgenic stock carrying a transcriptionally (and hence transpositionally) active L1 element needs to be established. One system, described in detail, is based on an ORFeus transgene driven by a constitutive promoter and marked by a retrotransposition indicator cassette, in which a GFP marker is disrupted by an intron (Supplementary Fig. 2 online) . Germline insertion frequency was estimated to be about 30%, and the genomic distribution of de novo retrotransposon insertions revealed ~28% and selection of mutants with the insertional mutagen; (ii) mutant pool propagation to provide sufficient generations for homozygote conversion; (iii) phenotypedriven screening of the biological pathway of interest to isolate candidate mutants; and (iv) candidate validation in terms of mutant locus identification, homozygosity status, phenotype rescue and functional relevance to the biology of interest. As discussed above, DNA transposons such as piggyBac have been shown to have a more random genome-wide distribution than retroviruses 38 . As a proof of principle, piggyBac mutagenesis in Blm-deficient embryonic stem cells was followed by screening for components involved in the DNA mismatch repair pathway. Four known components of the mismatch repair pathway genes were recovered 39 , whereas in a previous retrovirus-based screen, only one known component and a new gene were isolated 40 .
recessive, loss-of-function screens in the germline in vivo Screens using DNA transposons. In a two-component experimental system, in which transposition is controlled by trans-supplementation of the transposase (Fig. 1c) , two transgenic stocks are generated: a 'jumpstarter' strain that expresses the transposase and a 'mutator' strain that typically carries nonautonomous transposons equipped with gene trap cassettes 41 (Fig. 4) . These two stocks are crossed to bring the two components of the transposon system together, and transposition of the gene trap transposons is expected to occur in the sperm cells of F1 double-transgenic males (referred to as 'seed' mice; Fig. 4) . Such males are repeatedly crossed to wild-type females to segregate the different insertion events in their sperm cells in separate F2 animals (Fig. 4) . For the detection of gene trap insertions in vivo, fluorescent reporters such as GFP have been widely used. Transposon insertion sites can easily be established by PCR protocols from genomic DNA isolated from GFP-positive pups.
SB has been successfully used in mice that expressed the transposase either ubiquitously [42] [43] [44] [45] or in the male germline 46 . Recently, SB-based insertional mutagenesis was also established in the rat by using essentially the same experimental approach 47, 48 . In the mouse system, up to 90% of the F2 progeny can carry transposon insertions 43 , and a single sperm of a seed male can contain, on average, two insertion events 42 . The germline of such a founder was estimated to contain approximately 10,000 different mutations 44 . Notably, transposition of gene trap transposons identified mouse genes with ubiquitous and tissue-specific expression patterns, and mutant or lethal phenotypes were easily obtained by generating homozygous mice 44, 45, 49, 50 . Other studies 51 showed that local saturation mutagenesis of a genomic region is a realistic goal using the SB transposon system with a chromosomally resident transposon donor site. Insertional mutagenesis with SB in the germline of mice and rats has been approached with mutator 62, 63 are crossed with stocks that express the SB transposase to generate doubletransgenic mice ( Supplementary Fig. 3 online). Experimental tumors develop in somatic tissues of the double-transgenic mice as a result of dominant mutations.
In the published studies, somatic mobilization of the oncogene trap transposons accelerated tumor formation (mostly sarcomas) in a p19Arf-deficient cancerpredisposed genetic background 62 as well as the formation of leukemia and medulloblastoma in wild-type mice 63 . The next step in the procedure is to isolate the transposon insertions from tumor samples ( Supplementary Fig. 3 ) by using high-throughput PCR methods 64 and determine which one(s) are causative with respect to tumor formation by using common insertion site analysis. This analysis identifies repeated occurrence of insertions in particular genes in independent tumor samples. Candidate oncogenes are validated by transgenic models (Supplementary Fig. 3 ), for which transposons can be applied as powerful gene vectors 65 . To devise customized screens for cancer development, a current approach is to establish mouse lines conditionally expressing the transposase by using Cre recombinase-inducible transposase alleles. This approach has been elegantly applied to conditionally express the SB transposase in the liver and in the epithelial cells of the gastrointestinal tract in experimental mice by tissue-specific expression of Cre 66, 67 . The screens yielded genetic loci associated with hepatocellular carcinoma and colorectal cancer, and several of these are potential new targets for therapeutic intervention.
proJecTIons One obvious immediate application of transposon-based technologies is germline transgenesis in laboratory animals. Transgenic animal facilities worldwide could immediately adapt their standard operating procedure to the use of transposon-based plasmid vectors for highly efficient and reliable production of laboratory stocks. Furthermore, the current transposon technologies are immediately testable in large animal species of agricultural and biotechnological importance, including cattle, sheep and pig. The recently developed SB100X hyperactive transposon system yields unprecedented stable gene transfer efficiencies after nonviral gene delivery into therapeutically relevant primary cell types, including stem cells, and thus may facilitate the clinical implementation of ex vivo and in vivo gene therapies. Additionally, it is now becoming amenable to create libraries of gene knockouts and to thereby establish new models of human disease for therapeutic and pharmaceutical intervention in species in which embryonic stem cell and homologous recombination-based knockout technology has not been of the events occurring in RefSeq genes and a uniform ditribution of intragenic insertions along the targeted genes 60 .
From the perspective of their use as mutagenesis tools, L1 retrotransposons have several potential advantages. (i) Because of their 'copy-and-paste' mechanism of retrotransposition, the donor copy of the element is stable. (ii) Since donor elements can be driven by cellular promoters that are not transcribed, it is possible to design them so that they transpose only once ( Supplementary  Fig. 2 ). (iii) Retrotransposition can be controlled by the extent of RNA expression, for example, by using Cre-loxP technology 61 . One feature of L1 that can pose problems to its implementation as a mutagenesis tool is that ~90% of the progeny transposition events are associated with rearrangements (typically, 5′ truncations), and the complexities of these structures can create problems in determining sites of new insertion.
dominant, gain-of-function screens in the soma
Targeted over-and/or misexpression screens in somatic tissues of mice using SB has been shown to be especially useful for the generation of experimental cancers in animal models. Though this approach is similar to the application of retroviruses, transposable elements allow the recovery of tumors in tissues previously not amenable to such genomic approaches, including the liver and the brain. The 'oncogene trap' SB transposon (Fig. 2e) can induce loss-of-function mutations in tumor suppressor genes as well as gain-of-function overexpression of proto-oncogenes near the genomic insertion sites. Mutator lines with transposon For example, quantitative trait loci implicated in cardiovascular diseases could be dissected in the future using transposonmediated insertional mutagenesis in the rat system, the preferred model for cardiovascular biology 68 . Finally, recent advances in iPSC reprogramming should facilitate the identification of genetic determinants involved in physiological or pathological pathways in cells derived from patients with specific genetic diseases 69 . Thus, transposon-based technologies have enormous potential to develop powerful genomic tools with the vision of creating a bridge between physiology and genetics.
